Histone Deacetylase Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Class I, Class II, Class III, Class IV), By Application (Neurology, Oncology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2020-2031

Histone Deacetylase Inhibitors Market size was valued at US$ 2.9 billion in 2024 and is expected to reach US$ 5.3 billion by 2031, growing at a significant CAGR of 8.7% from 2025-2031. Histone deacetylase inhibitors are the products involved in inhibition of histone deacetylase, which removes acetyl groups from N-acetyl lysine amino acid present on the histone, and allows the histones to wrap DNA more tightly. Histone deacetylase inhibitors are used in the neurology and psychiatry as anti-epileptics and mood stabilizers.

Moreover, these are also used in the treatment of cancer, parasitic, and inflammatory diseases. Histone deacetylase (HDAC) is an enzyme that inhibits histone deacetylase by eliminating the scetyl group from the amino acid n-acetyl lysine. Histone deacetylase inhibitors are showing promise as a tool for cancer diagnosis, treatment, and prognosis. It's also used to treat haematological malignancies and plays a vital function in epigenetic and non-epigenetic regulation. Because of the rising incidence of various types of cancer and the growing need for improved cancer detection and therapies, the global market is booming.

Furthermore, one of the primary drivers of market expansion is an increase in R&D activities for cancer therapy and other neurological disorders. However, restrictive reimbursement regulations and HDAC inhibitor uncertainty may limit market expansion to some extent. Several histone deacetylase inhibitor compounds have been tested in clinical trials for various cancers in recent years. The chemical structure of these inhibitors is used to classify them. Hydroxamic acid-based drug are the most extensively studied class of histone deacetylase inhibitors.

Key Developments:

• In September 2024, Shuttle Pharmaceuticals, a specialty pharmaceutical company focused on improving outcomes for cancer patients undergoing radiation therapy, announced the issuance of U.S. Patent No. 12,077,515. The patent, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease," was officially issued on September 3, 2024. This patent strengthens Shuttle Pharma's intellectual property portfolio and supports its ongoing work in developing new therapeutics targeting histone deacetylase (HDAC) enzymes.
• In April 2024, the US FDA approved Italfarmaco's givinostat (Duvyzat), an HDAC inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged six and older.ITF Therapeutics, LLC will market and distribute DUVYZAT™ in the United States.